Magali Haas MSE, MD, PhD

Dr. Haas founded Orion Bionetworks in July 2012 and serves as its CEO and President. Orion Bionetworks was transformed to Cohen Veterans Bioscience in 2015 to specifically dedicate research to improving the detection and treatment of post-traumatic stress (PTS) and traumatic brain injury (TBI) and related co-morbidities so that the burden of these conditions may be lessened on service members, veterans, and their families.

Magali has over 15 years of pharmaceutical executive and clinical research experience, predominantly at Johnson & Johnson, where she assumed broad end-to-end development leadership roles in medical marketing, full clinical development, early development, and translational and biomarker sciences in psychiatry and neurology. She successfully filed NDAs in the US and Europe for risperidone indications in Autism, Adolescent Schizophrenia, Juvenile Bipolar Disorder and Conduct Disorders. She also led Development Teams evaluating compounds for Depression, Neuropathic Pain, Epilepsy, and Migraine Disorder.